Dr. Sara Nicole Horst, MD

Dr. Horst practices at Vanderbilt University Medical Center in Nashville, Tennessee, part of Vanderbilt University Medical Center.

Dr. Horst's NPI, 1265551295, was assigned on March 29, 2007. Dr. Horst graduated from Ohio State University College of Medicine in 2004. Dr. Horst holds Tennessee license 43742.

Dr. Horst's primary practice is Vanderbilt University Medical Center, at 1211 Medical Center Drive, Nashville, TN 37232 in Davidson County. The practice phone is (615) 322-3454.

Dr. Horst's primary practice is Vanderbilt University Medical Center in Nashville, Tennessee, part of Vanderbilt University Medical Center. The medical group on file is Vanderbilt University Medical Center. Dmand AI also links Dr. Horst to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Horst practices, 3 sites in all. Vendor and product names are available with a free account.

Gastroenterology is Dr. Horst's primary specialty in the NPI Registry, under taxonomy code 207RG0100X. Dmand AI has Dr. Horst's licenses on file in 2 states: Tennessee and Ohio.

CMS data shows 116 Medicare services from Dr. Horst across 3 procedure codes in 2024, for 102 Medicare patients. Medicare paid $9,887 for them.

CMS counts 102 Medicare patients who saw Dr. Horst in 2024. The largest group is 65 to 74, with 50 patients. 63% of them have high cholesterol, and 62% have high blood pressure. Their average risk score is 2.00, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Horst's median patient age at 49, with 56% women.

In 2024, Dr. Horst wrote 703 Medicare Part D claims for 121 patients. 52% of them were for generic drugs. CMS names the drug for 464 of them, across 14 drugs with 11 or more claims each, at $5,222,344 in total drug cost. In 2023, CMS named 556 claims across 21 drugs.

Dr. Horst accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Horst as offering telehealth. CMS counts 56 procedures of colonoscopy by Dr. Horst, more than 66% of the clinicians it reports for that procedure.

Dmand AI links 70 papers to Dr. Horst, published from 2012 to 2025. 2023 was the busiest year, with 8. The most frequent topics are Inflammatory Bowel Diseases, Crohn Disease and Telemedicine. Dr. Horst has published most often in Inflamm Bowel Dis. Dr. Horst's most frequent co-authors are David M.d. Schwartz, MD, Elizabeth Ann Scoville, MD and Robin L. Dalal, MD.

Dmand AI links Dr. Horst to 5 clinical trials. 1 is still active or recruiting. Conditions studied include Colitis, Ulcerative, Colitis and Inflammatory Bowel Diseases. Eli Lilly and Company sponsors the most, 2. Open Payments lists research payments to Dr. Horst that name 2 trials.

CMS Open Payments shows 307 general payments to Dr. Horst from 17 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 61% of the total. Abbvie Inc. paid the most, $97,022. It also lists 6 research payments totaling $22,184 from 2016 to 2021, naming 2 clinical trials.

Dr. Horst graduated from Ohio State University College of Medicine in 2004.